Ranitidine as adjuvant treatment in colorectal cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Short-term studies on histamine type 2 (H2) receptor antagonists and solid tumor survival are inconclusive.
• The efficacy of H2-receptor antagonist ranitidine on long-term survival in colorectal cancer patients requires further investigation.

Purpose of the Study:

• To evaluate the long-term survival efficacy of the H2-receptor antagonist ranitidine in patients with colorectal cancer.
• To assess the impact of ranitidine on overall survival, considering factors like perioperative blood transfusion and postoperative infectious complications.

Main Methods:

• A randomized, double-blind, placebo-controlled clinical study involving 740 patients undergoing elective resection of primary colorectal tumors.
• Patients received either ranitidine (100 mg IV then 150 mg oral twice daily) or placebo for 5 years; adjuvant therapy was not administered.
• Continuous follow-up for over 5 years with intention-to-treat analysis, including subgroup analysis of transfusion and infection complications.

Main Results:

• Ranitidine showed no significant effect on overall survival in univariate or multivariate analyses for all patients or curatively resected subgroups.
• A survival benefit was observed in non-transfused patients (HR 0.6; P=0.02) and non-transfused patients without postoperative infections (HR 0.6; P=0.01).
• Multivariate analysis confirmed ranitidine's independent beneficial effect on survival in non-transfused patients without postoperative complications (HR 0.6; P=0.04).

Conclusions:

• Ranitidine may prolong survival in specific colorectal cancer patient groups.
• The benefit is particularly noted in patients who undergo curative resection, do not receive perioperative blood transfusions, and do not develop postoperative infectious complications.